The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands

Drug Safety

Volumn 39, Issue 8, 2016, Pages 769-776

  Rolfes, Leàn ^a,b   van Hunsel, Florence ^a,b   Taxis, Katja ^b   van Puijenbroek, Eugène ^a,b  

^a NETHERLANDS PHARMACOVIGILANCE CENTRE LAREB   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE SODIUM; THYROXINE;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG PACKAGING; DRUG SAFETY; E-MAIL; FEMALE; FITNESS; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SOCIAL BEHAVIOR; VERY ELDERLY; DRUG SURVEILLANCE PROGRAM; PREGNANCY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; YOUNG ADULT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DRUG PACKAGING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTH STATUS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NETHERLANDS; PHARMACOVIGILANCE; PREGNANCY; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; THYROXINE; YOUNG ADULT;

EID: 84965032484     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-016-0422-0     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Measuring healthy days: population assessment of health-related quality of life. Atlanta: Centers for Disease Control and Prevention; 2000. http://www.cdc.gov/hrqol/pdfs/mhd.pdf. Accessed 21 June 2015.
2. Waller PC, Lee EH. Responding to drug safety issues. Pharmacoepidemiol Drug Saf. 1999;8(7):535–52.
3. Reporting adverse drug reactions: definitions of terms and criteria for their use. Geneva: Counsel for International Organizations of Medical Sciences (CIOMS); 1999. http://www.cioms.ch/publications/reporting_adverse_drug.pdf. Accessed 1 Aug 2015.
4. Carr AJ, Higginson IJ. Are quality of life measures patient centred? BMJ. 2001;322(7298):1357–60.
5. Baiardini I, Gaeta F, Molinengo G, Braido F, Canonica GW, Romano A. Quality-of-life issues in survivors to anaphylactic reactions to drugs. Allergy. 2015;70(7):877–9.
6. Lorimer S, Cox A, Langford NJ. A patient’s perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37(2):148–52.
7. Guo N, Marra F, Fitzgerald JM, Elwood RK, Marra CA. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis. Eur Respir J. 2010;36(1):206–8.
8. van Hunsel F, van der Welle C, Passier A, van Puijenbroek E, van Grootheest K. Motives for reporting adverse drug reactions by patient-reporters in the Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143–50.
9. ® [in Dutch]. 2015. http://www.lareb.nl/getmedia/e064e573-2776-402b-8661-f0c80d926a60/BCL_Rapport_Thyrax_juli_2015.pdf. Accessed 3 July 2015.
10. Lareb database. Thyrax (levothyroxine). 2016. http://databank.lareb.nl/Bijwerkingen/Result?formGroup=Tablet&atc=H03AA01&lang=en&drug=THYRAX%20%28LEVOTHYROXINE%29. Accessed 9 Feb 2016.
11. ® (levothryoxine) [in Dutch]. 2014. http://db.cbg-meb.nl/Bijsluiters/h08389.pdf. Accessed 16 June 2015.
12. Medicines Evaluation Board. MEB assessment study quality Thyrax [in Dutch]. 2015. http://www.cbg-meb.nl/actueel/nieuws/2015/07/30/cbg-beoordeling-onderzoek-kwaliteit-thyrax. Accessed 30 July 2015.
13. ® (levothyroxine) from a bottle to a blister. 2015. http://www.lareb.nl/Signalen/KWB_2014_4_Thyrax_bottle_2. Accessed 16 June 2015.
14. avotros. Television broadcoast Adverse Drug Reactions of the drug Thyrax (RADAR: Bijwerkingen schildkliermedicijn Thyrax) [in Dutch]. 2015. http://www.radartv.nl/uitzending/archief/detail/aflevering/16-02-2015/bijwerkingen-schildkliermedicijn-thyrax/. Accessed 16 June 2015.
15. Faasse K, Cundy T, Petrie KJ. Medicine and the media. Thyroxine: anatomy of a health scare. BMJ. 2009;339:b5613.
16. Faasse K, Gamble G, Cundy T, Petrie KJ. Impact of television coverage on the number and type of symptoms reported during a health scare: a retrospective pre-post observational study. BMJ Open. 2012;2(4). doi:10.1136/bmjopen-2012-001607.
17. Rolfes L, van Hunsel F, van Grootheest K, van Puijenbroek E. Feedback for patients reporting adverse drug reactions; satisfaction and expectations. Expert Opin Drug Saf. 2015;14(5):625–32.
18. Harmark L, van HF, Grundmark B. ADR reporting by the general public: lessons learnt from the Dutch and Swedish systems. Drug Saf. 2015;38(4):337–47.
19. van Weel C, König-Zahn C, Touw-Otten FWMM, et al. Measuring functional status with the COOP/WONCA charts: a manual. 2012. http://www.gezondheidsvaardigheden.nl/wordpress/wp-content/uploads/2012/10/Handleiding_coopwonca2edruk.pdf. Accessed 18 Feb 2016.
20. Survey Monkey. 2015. http://www.surveymonkey.com. Accessed 1 Feb 2015.
21. The Central Commitee on Research Involving Human Subjects (CCMO). Guideline CCMO. 2012. http://www.ccmo.nl/. Accessed 12 Sep 2015.
22. Slotboom A. Statistics in words. 2nd ed. Groningen: Wolters-Noordhoff bv Groningen; 1996. p. 11.
23. Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49(6):929–39.
24. van Hunsel F, Passier A, van Grootheest AC. Comparing patients’ and healthcare professionals’ ADR reports after media attention. The broadcast of a Dutch television programma about the benefits and risks of statins as an example. Br J Clin Pharmacol. 2009;67(5):558–64.
25. Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1–iv.
26. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56(5):395–407.
27. Wu YP, Follansbee-Junger K, Rausch J, Modi A. Parent and family stress factors predict health-related quality in pediatric patients with new-onset epilepsy. Epilepsia. 2014;55(6):866–77.
28. Davis KM, Kelly SP, Luta G, Tomko C, Miller AB, Taylor KL. The association of long-term treatment-related side effects with cancer-specific and general quality of life among prostate cancer survivors. Urology. 2014;84(2):300–6.
29. Ernst ME, Iyer SS, Doucette WR. Drug-related problems and quality of life in arthritis and low back pain sufferers. Value Health. 2003;6(1):51–8.
30. Blome C, Augustin M. Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health. 2015;18(1):110–5.
31. Dutch National Institute for Health and Environment. Dutch national puplic health compass. 2016. http://www.nationaalkompas.nl/algemeen/menu-rechts/english/. Accessed 8 Jan 2016.
32. Rolfes L, Wilkes S, van Hunsel F, van Puijenbroek E, van Grootheest K. Important information regarding reporting of adverse drug reactions: a qualitative study. Int J Pharm Pract. 2014;22(3):231–3.
33. Rolfes L, van Hunsel F, Wilkes S, van Grootheest K, van Puijenbroek E. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information. Pharmacoepidemiol Drug Saf. 2015;24(2):152–8.
34. Härmark L, van Grootheest K. Web-based intensive monitoring: from passive to active drug surveillance. Expert Opin Drug Saf. 2012;11(1):45–51.